Clinical trials: BCG
BCG Vaccination Reaction
Safety and Tuberculin Conversion Following BCG Vaccination
The study is an bridging study, observer-blind, randomized, controlled prospective intervention study. The primary objective is evaluate the safety of BCG Vaccine Vial (Bio Farma).
- Trial name
- NCT05124340
- Testing
- BCG vial vaccine, BCG ampoule vaccine
- Where
- Indonesia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Lower Urinary Tract Symptoms, Bladder Carcinoma
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Common local side effects are generally seen during induction and during the first 6 months of BCG maintenance. BCG-related cystitis is frequent and unavoidable.
- Conditions
- Lower Urinary Tract Symptoms, Bladder Carcinoma, BCG
- Trial name
- NCT03549650
- Testing
- Pentosan Polysulfate Na 100Mg Cap
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
BCG Vaccination Reaction
BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects .
Study of BCG Vaccination scars of under five years old children . Estimation of the frequency of children without BCG scar after BCG vaccine . Evaluation of factors which may affect scar formation .
- Trial name
- bcgscars (NCT03548233)
- Testing
- bcg vaccine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
LTBI, BCG Vaccination Reaction
Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)
TB-reactive immune cells will be tested in a multiparametric flow cytometry to distinguish an immune response for antigens of Mycobacterium spp. in TB disease/latent infection or a reaction after BCG vaccine.
- Conditions
- LTBI, BCG Vaccination Reaction, TB
- Trial name
- NCT04673227
- Testing
- Blood draw
- Where
- 2 sites in Czechia
- Volunteers
- 120 people
- Sponsor
- Thomayer University Hospital
Covid19, BCG Vaccination Reaction
Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland
Countries that have not carried out universal mass vaccination against tuberculosis (BCG) have been shown to have higher incidence and death rates due to COVID-19 than countries with mass, long-term BCG immunization programmes.
- Conditions
- Covid19, BCG Vaccination Reaction, SARS-CoV Infection
- Trial name
- NCT04648800
- Testing
- BCG-10 vaccine, 0.9% saline
- Where
- 6 sites in Poland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hanna Czajka
BCG, COVID-19
Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers
In Mexico the total number of confirmed cases of COVID-19 is 232, 000 and 28,510 deaths. Health workers are at high risk of COVID-19 infection. Their absence from work dramatically limits the ability to contain the disease.
- Conditions
- BCG, COVID-19, SARS-CoV2, Corona Virus Infection
- Trial name
- NCT04461379
- Testing
- BCG vaccine
- Where
- Mexico
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Covid 19, BCG Vaccination
Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study
Covid-19 In Tunisia: AN Observational Cross-Sectional Registry Study
- Trial name
- CONNAITRE (NCT04384614)
- Testing
- Test PCR, TDR, Clinical Examination
- Where
- Tunisia
- Sponsor
- Direction des Soins de Santé de Base
Bladder Cancer, Bladder Neoplasm
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate…
- Conditions
- Bladder Cancer, Bladder Neoplasm, Bladder Tumors, Cancer of Bladder
- Trial name
- RITE-USA (NCT03335059)
- Testing
- Synergo® RITE + MMC
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Medical Enterprises Ltd.
COVID-19, BCG Vaccination
Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?
There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is…
- Trial name
- NCT04347876
- Testing
- Tuberculin test
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Tuberculosis, BCG Vaccination
Clinical Study to Evaluate Safety and Immunogenicity of Bacillus Calmette-Guerin (BCG) Delivery Via Novel Micronjet600 Device Compared to Those Via Conventional Needle
The purpose of this study is to evaluate safety and immunogenicity of Bacillus Calmette-Guerin (BCG) delivery via Novel Micronjet600 device compared to those via conventional needle.
- Trial name
- NCT04064554
- Testing
- BCG vaccination with MicronJet600, BCG vaccination with conventional needle
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yonsei University
BCG Infection, Reaction - Vaccine
A Study of the Interaction Between BCG And MenC Immunisation: BAM
The Bacille Calmette-Guérin (BCG) vaccine is the only vaccine licenced to prevent tuberculosis (TB). The stimulus it gives to the immune system allows it to respond more effectively to a subsequent infection with TB.
- Conditions
- BCG Infection, Reaction - Vaccine, Immune Response
- Trial name
- BAM (NCT02002156)
- Testing
- BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
This is a phase Ib, open-label, single-arm, single-center study conducted in Canada. Subjects with NMIBC (Ta, T1, and/or Tis) who are not candidates for or have refused radical cystectomy will be eligible for participation in the…
- Trial name
- NCT03053635
- Testing
- TLD1433 infusion and photodynamic therapy (PDT) treatment
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Theralase® Technologies Inc.
Non-Muscle-invasive Bladder Cancer (NMIBC), Bacillus Calmette-Guerin (BCG) Cystitis
Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?
Compare the different supposed clinical treatment of side effects associated with intravesical BCG by levofloxacin (quinolones) vs solifenacin (selective anti-muscarinic) vs lornoxicam (NSAID)
- Conditions
- Non-Muscle-invasive Bladder Cancer (NMIBC), Bacillus Calmette-Guerin (BCG) Cystitis, Intra-vesical Instillation
- Trial name
- NCT03038321
- Testing
- sofenacin, Tavanic, Xefo
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Mansoura University
Oncology, Bladder Cancer
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high…
- Conditions
- Oncology, Bladder Cancer, Superficial Bladder Cancer, Recurrence
- Trial name
- NCT03121768
- Where
- Egypt
- Volunteers
- 761 people
- Sponsor
- Mansoura University
Non Muscle Invasive Bladder Cancer, Treatment by BCG
Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC
Intravesical BCG immunotherapy is used after transurethral resection (TUR) for the prevention of recurrence of NMIBC. BCG treatment is usually started a few weeks after TUR and is given once a week for 6 weeks.
- Trial name
- CEPHEID (NCT02895620)
- Testing
- Xpert bladder Test
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut Claudius Regaud
BCG Vaccination
Role of BCG as Booster Vaccination
The BCG (bacillus Calmette-Guerin) vaccine is used for the protection against tuberculosis. Apart from it's protective effect against tuberculosis BCG vaccine has been shown to have non-specific effects on the innate immune…
- Trial name
- NCT02175420
- Testing
- BCG, TFV
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Poisoning by BCG Vaccine
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
The purpose of this study is to evaluate a possible role of intravesical Hyaluronic Acid in reducing local toxicity of Bacillus Calmette Guerin (BCG) used to treat bladder urothelial cell carcinoma.
- Trial name
- NCT02207608
- Testing
- Hyaluronic Acid, BCG (Immucist®)
- Volunteers
- 30 people
- Sponsor
- University of Rome Tor Vergata